Clinical trials: Respiratory Exacerbation
Asthma
Asthma Exacerbation Study
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
- Trial name
- NCT01086384
- Testing
- Fluticasone Furoate/GW642444, Fluticasone furoate
- Where
- 183 sites in United States, Argentina and 9 more
- Volunteers
- 2,020 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older.
- Trial name
- NCT03451045
- Testing
- Lenabasum 20 mg, Lenabasum 5 mg
- Where
- 105 sites in United States, Austria and 19 more
- Volunteers
- 447 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Airway Obstruction
Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
It has been observed that COPD exacerbations are under-reported in China. One of the reasons for this is Chinese subjects with COPD cannot describe the symptoms of exacerbation mentioned in English.
- Trial name
- NCT03170999
- Testing
- Focus group interview, Draft item set, Candidate item set
- Where
- 3 sites in China
- Volunteers
- 199 people
- Sponsor
- GlaxoSmithKline
COPD
This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea
This study is designed as a multicenter, prospective and retrospective and descriptive epidemiology study. This study is planned to evaluate 2 years of exacerbation in COPD patients and to investigate correlation of COPD disease…
- Trial name
- EPOCH (NCT01419379)
- Where
- 14 sites in South Korea
- Volunteers
- 1,118 people
- Sponsor
- Takeda
Pulmonary Disease, Chronic Obstructive
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT00361959
- Testing
- Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg
- Where
- 166 sites in Austria, Belgium and 18 more
- Volunteers
- 1,270 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00076089
- Testing
- Roflumilast
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Asthma
Exacerbation Risk in Asthma
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
- Trial name
- NCT05501639
- Testing
- tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
- Where
- United States
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00115492
- Testing
- Fluticasone Propionate/Salmeterol Combination Product, Salmeterol
- Where
- 110 sites in United States, Canada
- Volunteers
- 797 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD).
- Trial name
- VIGILANT (NCT07177339)
- Testing
- Depemokimab
- Where
- 121 sites in United States, Australia and 11 more
- Volunteers
- 1,196 people
- Sponsor
- GlaxoSmithKline
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Pulmonary Disease, Chronic Obstructive
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
The timing of initiating short-term treatment for COPD exacerbations with oral corticosteroids and/or antibiotic therapy has been shown to influence the recovery time of exacerbations with early initiation of exacerbation therapy…
- Trial name
- NCT01431911
- Testing
- Early maintenance treatment, Delayed Maintenance treatment
- Volunteers
- 3,806 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess the efficacy and safety of the intravenous drip infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) in a multicenter, double-blind, randomized…
- Trial name
- NCT02739165
- Testing
- ART-123
- Where
- 26 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline